CD19 and acute lymphoblastic leukemia: Even in CD19-CAR T cell targeting of Acute Lymphoblastic Leukaemia, 40% of patients relapse of which 30% were antigen-negative tumors,27 and therefore it is certain that combination approaches will require multitargeting of tumor antigens for heterogeneous tumors like DIPG.